Robust affiliation between malnutrition, irritation, and atherosclerosis in power renal failure.
Background
Atheroscleroticcardiovascular illness and malnutrition are widely known as main causes of the elevated morbidity and mortality noticed in uremic sufferers. C-reactive protein (CRP), an acute-phase protein, is a predictor of cardiovascular mortality in nonrenal affected person populations. In power renal failure (CRF), the prevalence of an acute-phase response has been related to an elevated mortality.
METHODS
100 and 9 predialysis sufferers (age 52 +/- 1 years) with terminal CRF (glomerular filtration charge 7 +/- 1 ml/min) have been studied. Through the use of noninvasive B-mode ultrasonography, the cross-sectional carotid intima-media space was calculated, and the presence or absence of carotid plaques was decided.
Dietary standing was assessed by subjective world evaluation (SGA), dual-energy x-ray absorptiometry (DXA), serum albumin, serum creatinine, serum urea, and 24-hour urine urea excretion. The presence of an inflammatory response was assessed by CRP, fibrinogen (N = 46), and tumor necrosis factor-alpha (TNF-alpha; N = 87). Lipid parameters, together with Lp(a) and apo(a)-isoforms, in addition to markers of oxidative stress (autoantibodies in opposition to oxidized low-density lipoprotein and vitamin E), have been additionally decided.
RESULTS
In contrast with wholesome controls, CRF sufferers had an elevated imply carotid intima-media space (18.3 +/- 0.6 vs. 13.2 +/- 0.7 mm2, P < 0.0001) and a better prevalence of carotid plaques (72 vs. 32%, P = 0.001). The prevalence of malnutrition (SGA 2 to 4) was 44%, and 32% of all sufferers had an acute-phase response (CRP>> or = 10 mg/liter).
Malnourished sufferers had larger CRP ranges (23 +/- Three vs. 13 +/- 2 mg/liter, P < 0.01), elevated calculated intima-media space (20.2 +/- 0.eight vs. 16.9 +/- 0.7 mm2, P < 0.01) and a better prevalence of carotid plaques (90 vs. 60%, P < 0.0001) in contrast with well-nourished sufferers.
Throughout stepwise multivariate evaluation adjusting for age and gender, vitamin E (P < 0.05) and CRP (P < 0.05) remained related to an elevated intima-media space. The presence of carotid plaques was considerably related to age (P < 0.001), log oxidized low-density lipoprotein (oxLDL; P < 0.01), and small apo(a) isoform dimension (P < 0.05) in a multivariate logistic regression mannequin.
CONCLUSIONS
These outcomes point out that the quickly growing atherosclerosis in superior CRF seems to be attributable to a synergism of various mechanisms, similar to malnutrition, irritation, oxidative stress, and genetic parts. Aside from basic danger components, low vitamin E ranges and elevated CRP ranges are related to an elevated intima-media space, whereas small molecular weight apo(a) isoforms and elevated ranges of oxLDL are related to the presence of carotid plaques.
GPR61 Antibody |
|||
DF2810-200ul | Affinity Biosciences | 200ul | EUR 350 |
GPR61 Antibody |
|||
DF2755 | Affinity Biosciences | 100ul | EUR 280 |
Description: Human,Mouse |
GPR61 Antibody |
|||
DF2810 | Affinity Biosciences | 100ul | EUR 280 |
Description: Human,Mouse |
GPR61 Conjugated Antibody |
|||
C44933 | SAB | 100ul | EUR 476.4 |
GPR61 Polyclonal Antibody |
|||
ABP58695-003ml | Abbkine | 0.03ml | EUR 189.6 |
Description: A polyclonal antibody for detection of GPR61 from Human, Mouse. This GPR61 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human GPR61 protein at amino acid sequence of 190-270 |
GPR61 Polyclonal Antibody |
|||
ABP58695-01ml | Abbkine | 0.1ml | EUR 346.8 |
Description: A polyclonal antibody for detection of GPR61 from Human, Mouse. This GPR61 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human GPR61 protein at amino acid sequence of 190-270 |
GPR61 Polyclonal Antibody |
|||
ABP58695-02ml | Abbkine | 0.2ml | EUR 496.8 |
Description: A polyclonal antibody for detection of GPR61 from Human, Mouse. This GPR61 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human GPR61 protein at amino acid sequence of 190-270 |
GPR61 Polyclonal Antibody |
|||
ES11477-100ul | ELK Biotech | 100ul | EUR 334.8 |
Description: A Rabbit Polyclonal antibody against GPR61 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA |
GPR61 Polyclonal Antibody |
|||
ES11477-50ul | ELK Biotech | 50ul | EUR 248.4 |
Description: A Rabbit Polyclonal antibody against GPR61 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA |
GPR61 Polyclonal Antibody |
|||
E11-202531 | EnoGene | 100ug/100ul | EUR 225 |
Description: Available in various conjugation types. |
GPR61 (untagged)-Human G protein-coupled receptor 61 (GPR61) |
|||
SC106692 | Origene Technologies GmbH | 10 µg | Ask for price |
GPR61 (untagged)-Human G protein-coupled receptor 61 (GPR61) |
|||
SC317735 | Origene Technologies GmbH | 10 µg | Ask for price |
Probable G-Protein Coupled Receptor 61 (GPR61) Antibody |
|||
20-abx147479 | Abbexa |
|
|
Probable G-Protein Coupled Receptor 61 (GPR61) Antibody |
|||
abx147480-100ug | Abbexa | 100 ug | EUR 526.8 |
Polyclonal GPR61 Antibody (C-Terminus) |
|||
APR16588G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (C-Terminus). This antibody is tested and proven to work in the following applications: |
Polyclonal GPR61 Antibody (C-Terminus) |
|||
APR16589G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (C-Terminus). This antibody is tested and proven to work in the following applications: |
Polyclonal GPR61 Antibody (N-Terminus) |
|||
APR16592G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (N-Terminus). This antibody is tested and proven to work in the following applications: |
GPR61 Recombinant Protein (Rat) |
|||
RP203447 | ABM | 100 ug | Ask for price |
GPR61 Recombinant Protein (Human) |
|||
RP013882 | ABM | 100 ug | Ask for price |
GPR61 Recombinant Protein (Mouse) |
|||
RP139673 | ABM | 100 ug | Ask for price |
Polyclonal GPR61 Antibody (Cytoplasmic Domain) |
|||
APR16590G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (Cytoplasmic Domain). This antibody is tested and proven to work in the following applications: |
Polyclonal GPR61 Antibody (Extracellular Domain) |
|||
APR16591G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (Extracellular Domain). This antibody is tested and proven to work in the following applications: |
GPR61 (GFP-tagged) - Human G protein-coupled receptor 61 (GPR61) |
|||
RG209672 | Origene Technologies GmbH | 10 µg | Ask for price |
Gpr61 (untagged) - Mouse G protein-coupled receptor 61 (Gpr61), (10ug) |
|||
MC216046 | Origene Technologies GmbH | 10 µg | Ask for price |
Human GPR61 Protein Lysate 20ug |
|||
IHUGPR61PLLY20UG | Innovative research | each | EUR 213 |
Description: Human GPR61 Protein Lysate 20ug |
OCOA07698-20UG - GPR61 Protein Lysate |
|||
OCOA07698-20UG | Aviva Systems Biology | 20ug | EUR 169 |
Gpr61 (GFP-tagged) - Mouse G protein-coupled receptor 61 (Gpr61), (10ug) |
|||
MG216498 | Origene Technologies GmbH | 10 µg | Ask for price |
GPR61 (Myc-DDK-tagged)-Human G protein-coupled receptor 61 (GPR61) |
|||
RC209672 | Origene Technologies GmbH | 10 µg | Ask for price |
Gpr61 (Myc-DDK-tagged) - Mouse G protein-coupled receptor 61 (Gpr61) |
|||
MR216498 | Origene Technologies GmbH | 10 µg | Ask for price |
GPR61 Rabbit Polyclonal (N-Terminus) Antibody |
|||
TA316841 | Origene Technologies GmbH | 50 µg | Ask for price |
GPR61 Rabbit Polyclonal (C-Terminus) Antibody |
|||
TA316842 | Origene Technologies GmbH | 50 µg | Ask for price |
GPR61 Rabbit Polyclonal (C-Terminus) Antibody |
|||
TA316843 | Origene Technologies GmbH | 50 µg | Ask for price |
Gpr61 (untagged ORF) - Rat G protein-coupled receptor 61 (Gpr61), (10 ug) |
|||
RN213131 | Origene Technologies GmbH | 10 µg | Ask for price |
GPR61 Rabbit Polyclonal (Cytoplasmic Domain) Antibody |
|||
TA316845 | Origene Technologies GmbH | 50 µg | Ask for price |
GPR61 Rabbit Polyclonal (Extracellular Domain) Antibody |
|||
TA316844 | Origene Technologies GmbH | 50 µg | Ask for price |
ARP95145_P050-25UL - GPR61 Antibody - N-terminal region |
|||
ARP95145_P050-25UL | Aviva Systems Biology | 25ul | EUR 99 |
GPR61 Protein Vector (Rat) (pPM-C-HA) |
|||
PV271268 | ABM | 500 ng | EUR 723.6 |
Gpr61 (Myc-DDK-tagged ORF) - Rat G protein-coupled receptor 61 (Gpr61), (10 ug) |
|||
RR213131 | Origene Technologies GmbH | 10 µg | Ask for price |
GPR61 Protein Vector (Rat) (pPB-C-His) |
|||
PV271266 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Rat) (pPB-N-His) |
|||
PV271267 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Rat) (pPM-C-His) |
|||
PV271269 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Human) (pPM-C-HA) |
|||
PV018511 | ABM | 500 ng | EUR 394.8 |
GPR61 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV186236 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Human) (pPB-C-His) |
|||
PV018509 | ABM | 500 ng | EUR 394.8 |
GPR61 Protein Vector (Human) (pPB-N-His) |
|||
PV018510 | ABM | 500 ng | EUR 394.8 |
GPR61 Protein Vector (Human) (pPM-C-His) |
|||
PV018512 | ABM | 500 ng | EUR 394.8 |
GPR61 Protein Vector (Mouse) (pPB-C-His) |
|||
PV186234 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Mouse) (pPB-N-His) |
|||
PV186235 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Mouse) (pPM-C-His) |
|||
PV186237 | ABM | 500 ng | EUR 723.6 |
Lenti ORF clone of Gpr61 (mGFP-tagged) - Mouse G protein-coupled receptor 61 (Gpr61) |
|||
MR216498L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Gpr61 (Myc-DDK-tagged) - Mouse G protein-coupled receptor 61 (Gpr61) |
|||
MR216498L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Gpr61 (mGFP-tagged ORF) - Rat G protein-coupled receptor 61 (Gpr61), (10 ug) |
|||
RR213131L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Protein GPR107 (GPR107) Antibody |
|||
abx233589-100ug | Abbexa | 100 ug | EUR 661.2 |
Protein GPR108 (GPR108) Antibody |
|||
abx233590-100ug | Abbexa | 100 ug | EUR 610.8 |
Protein GPR108 (GPR108) Antibody |
|||
20-abx324350 | Abbexa |
|
|
Protein GPR107 (GPR107) Antibody |
|||
20-abx324945 | Abbexa |
|
|
Protein GPR107 (GPR107) Antibody |
|||
abx031441-400ul | Abbexa | 400 ul | EUR 627.6 |
Protein GPR107 (GPR107) Antibody |
|||
abx031441-80l | Abbexa | 80 µl | EUR 343.2 |
Protein GPR108 (GPR108) Antibody |
|||
20-abx015294 | Abbexa |
|
|
Lenti ORF particles, Gpr61 (GFP-tagged) - Mouse G protein-coupled receptor 61 (Gpr61), 200ul, >10^7 TU/mL |
|||
MR216498L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF clone of Gpr61 (Myc-DDK-tagged ORF) - Rat G protein-coupled receptor 61 (Gpr61), (10 ug) |
|||
RR213131L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, GPR61 (mGFP-tagged) - Human G protein-coupled receptor 61 (GPR61), 200ul, >10^7 TU/mL |
|||
RC209672L2V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, GPR61 (mGFP-tagged) - Human G protein-coupled receptor 61 (GPR61), 200ul, >10^7 TU/mL |
|||
RC209672L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Gpr61 (GFP-tagged ORF) - Rat G protein-coupled receptor 61 (Gpr61), 200ul, >10^7 TU/mL |
|||
RR213131L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, GPR61 (Myc-DDK tagged) - Human G protein-coupled receptor 61 (GPR61), 200ul, >10^7 TU/mL |
|||
RC209672L1V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, GPR61 (Myc-DDK tagged) - Human G protein-coupled receptor 61 (GPR61), 200ul, >10^7 TU/mL |
|||
RC209672L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Gpr61 (Myc-DDK-tagged) - Mouse G protein-coupled receptor 61 (Gpr61), 200ul, >10^7 TU/mL |
|||
MR216498L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Anti-GPR61 antibody |
|||
STJ192635 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Unconjugated Rabbit polyclonal to GPR61 |
Lenti ORF particles, Gpr61 (Myc-DDK-tagged ORF) - Rat G protein-coupled receptor 61 (Gpr61), 200ul, >10^7 TU/mL |
|||
RR213131L3V | Origene Technologies GmbH | 200 µl | Ask for price |
GPR61 siRNA |
|||
20-abx918539 | Abbexa |
|
|
GPR61 siRNA |
|||
20-abx918540 | Abbexa |
|
|
Protein Wntless Homolog (GPR177) Antibody |
|||
abx233601-100ug | Abbexa | 100 ug | EUR 610.8 |
Integral Membrane Protein GPR137 (GPR137) Antibody |
|||
abx233594-100ug | Abbexa | 100 ug | EUR 577.2 |
Integral Membrane Protein GPR175 (GPR175) Antibody |
|||
abx216260-100ug | Abbexa | 100 ug | EUR 526.8 |
Integral Membrane Protein GPR180 (GPR180) Antibody |
|||
20-abx133786 | Abbexa |
|
|
Integral Membrane Protein GPR175 (GPR175) Antibody |
|||
20-abx121124 | Abbexa |
|
|
Integral Membrane Protein GPR175 (GPR175) Antibody |
|||
20-abx119147 | Abbexa |
|
|
Integral Membrane Protein GPR137 (GPR137) Antibody |
|||
20-abx112628 | Abbexa |
|
|
Integral Membrane Protein GPR137 (GPR137) Antibody |
|||
abx028020-400ul | Abbexa | 400 ul | EUR 627.6 |
Integral Membrane Protein GPR137 (GPR137) Antibody |
|||
abx028020-80l | Abbexa | 80 µl | EUR 343.2 |
Integral Membrane Protein GPR175 (GPR175) Antibody |
|||
20-abx015315 | Abbexa |
|
|
Integral Membrane Protein GPR180 (GPR180) Antibody |
|||
abx034515-400ul | Abbexa | 400 ul | EUR 627.6 |
Integral Membrane Protein GPR180 (GPR180) Antibody |
|||
abx034515-80l | Abbexa | 80 µl | EUR 343.2 |
Malnutrition-inflammation complicated syndrome in dialysis sufferers: causes and penalties.
Atherosclerotic heart problems and malnutrition are widely known as main causes of the elevated morbidity and mortality noticed in uremic sufferers. C-reactive protein (CRP), an acute-phase protein, is a predictor of cardiovascular mortality in nonrenal affected person populations. In power renal failure (CRF), the prevalence of an acute-phase response has been related to an elevated mortality.
METHODS
100 and 9 predialysis sufferers (age 52 +/- 1 years) with terminal CRF (glomerular filtration charge 7 +/- 1 ml/min) have been studied. Through the use of noninvasive B-mode ultrasonography, the cross-sectional carotid intima-media space was calculated, and the presence or absence of carotid plaques was decided.
Dietary standing was assessed by subjective world evaluation (SGA), dual-energy x-ray absorptiometry (DXA), serum albumin, serum creatinine, serum urea, and 24-hour urine urea excretion.
The presence of an inflammatory response was assessed by CRP, fibrinogen (N = 46), and tumor necrosis factor-alpha (TNF-alpha; N = 87). Lipid parameters, together with Lp(a) and apo(a)-isoforms, in addition to markers of oxidative stress (autoantibodies in opposition to oxidized low-density lipoprotein and vitamin E), have been additionally decided.
RESULTS
In contrast with wholesome controls, CRF sufferers had an elevated imply carotid intima-media space (18.3 +/- 0.6 vs. 13.2 +/- 0.7 mm2, P < 0.0001) and a better prevalence of carotid plaques (72 vs. 32%, P = 0.001). The prevalence of malnutrition (SGA 2 to 4) was 44%, and 32% of all sufferers had an acute-phase response (CRP>> or = 10 mg/liter).
Malnourished sufferers had larger CRP ranges (23 +/- Three vs. 13 +/- 2 mg/liter, P < 0.01), elevated calculated intima-media space (20.2 +/- 0.eight vs. 16.9 +/- 0.7 mm2, P < 0.01) and a better prevalence of carotid plaques (90 vs. 60%, P < 0.0001) in contrast with well-nourished sufferers.
Throughout stepwise multivariate evaluation adjusting for age and gender, vitamin E (P < 0.05) and CRP (P < 0.05) remained related to an elevated intima-media space. The presence of carotid plaques was considerably related to age (P < 0.001), log oxidized low-density lipoprotein (oxLDL; P < 0.01), and small apo(a) isoform dimension (P < 0.05) in a multivariate logistic regression mannequin.
CONCLUSIONS
These outcomes point out that the quickly growing atherosclerosis in superior CRF seems to be attributable to a synergism of various mechanisms, similar to malnutrition, irritation, oxidative stress, and genetic parts. Aside from basic danger components, low vitamin E ranges and elevated CRP ranges are related to an elevated intima-media space, whereas small molecular weight apo(a) isoforms and elevated ranges of oxLDL are related to the presence of carotid plaques.
- Protein-energy malnutrition (PEM) and irritation are widespread and often concurrent in upkeep dialysis sufferers. Many components that seem to result in these 2 situations overlap, as do evaluation instruments and such standards for detecting them as hypoalbuminemia.
- Each these situations are associated to poor dialysis end result. Low urge for food and a hypercatabolic state are amongst widespread options. PEM in dialysis sufferers has been advised to be secondary to irritation; nonetheless, the proof isn’t conclusive, and an equicausal standing and even reverse causal route is feasible.
- Therefore, malnutrition-inflammation complicated syndrome (MICS) is an applicable time period. Attainable causes of MICS embody comorbid diseases, oxidative and carbonyl stress, nutrient loss by means of dialysis, anorexia and low nutrient consumption, uremic toxins, decreased clearance of inflammatory cytokines, quantity overload, and dialysis-related components.
- MICS is believed to be the primary reason behind erythropoietin hyporesponsiveness, excessive charge of cardiovascular atherosclerotic illness, decreased high quality of life, and elevated mortality and hospitalization in dialysis sufferers.
- As a result of MICS results in a low physique mass index, hypocholesterolemia, hypocreatininemia, and hypohomocysteinemia, a “reverse epidemiology” of cardiovascular dangers can happen in dialysis sufferers.
- Due to this fact, weight problems, hypercholesterolemia, and elevated blood ranges of creatinine and homocysteine look like protecting and paradoxically related to a greater end result.
- There isn’t a consensus about tips on how to decide the diploma of severity of MICS or tips on how to handle it. A number of diagnostic instruments and therapy modalities are mentioned. Profitable administration of MICS might ameliorate the cardiovascular epidemic and poor end result in dialysis sufferers.
- Scientific trials specializing in MICS and its doable causes and penalties are urgently required to enhance poor medical end result in dialysis sufferers.
Recombinant EBV EBNA1 Protein, His, E.coli-100ug |
|||
QP11731-100ug | EnQuireBio | 100ug | EUR 381.6 |
Recombinant EBV EBNA1 Protein, His, E.coli-500ug |
|||
QP11731-500ug | EnQuireBio | 500ug | EUR 1034.4 |
EBV EBNA1 antibody |
|||
20-EG46 | Fitzgerald | 1 mg | EUR 139.2 |
Description: Goat polyclonal EBV EBNA1 antibody |
Recombinant EBV EBNA1 Mosaic Protein, His, E.coli-1mg |
|||
QP11732-1mg | EnQuireBio | 1mg | EUR 1273.2 |
Recombinant EBV EBNA1 Mosaic Protein, His, E.coli-100ug |
|||
QP11732-100ug | EnQuireBio | 100ug | EUR 261.6 |
Recombinant EBV EBNA1 Mosaic Protein, His, E.coli-500ug |
|||
QP11732-500ug | EnQuireBio | 500ug | EUR 795.6 |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [GST] |
|||
VAng-Lsx0111-100g | Creative Biolabs | 100 µg | EUR 759.6 |
Description: EBV EBNA1 Mosaic protein [GST], recombinant protein from E. coli. |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [GST] |
|||
VAng-Lsx0111-500g | Creative Biolabs | 500 µg | EUR 2419.2 |
Description: EBV EBNA1 Mosaic protein [GST], recombinant protein from E. coli. |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [His] |
|||
VAng-2528Lsx-100g | Creative Biolabs | 100 µg | EUR 555.6 |
Description: EBV EBNA1 Mosaic protein, His tag at C-terminus, recombinant protein from E. coli. |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [His] |
|||
VAng-2528Lsx-1mg | Creative Biolabs | 1 mg | EUR 3360 |
Description: EBV EBNA1 Mosaic protein, His tag at C-terminus, recombinant protein from E. coli. |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [His] |
|||
VAng-2528Lsx-500g | Creative Biolabs | 500 µg | EUR 2040 |
Description: EBV EBNA1 Mosaic protein, His tag at C-terminus, recombinant protein from E. coli. |
EBV EBNA protein |
|||
30-AE46 | Fitzgerald | 200 ug | EUR 900 |
Description: Purified recombinant EBV EBNA protein |
EBNA1 protein |
|||
30-1925 | Fitzgerald | 500 ug | EUR 678 |
Description: Purified Recombinant EBNA1 protein |
EBNA1 protein (His tag) |
|||
80-1340 | Fitzgerald | 100 ug | EUR 289.2 |
Description: Purified recombinant EBNA1 protein (His tag) |
Recombinant EBNA1 Protein [GST] |
|||
VAng-Lsx0122-100g | Creative Biolabs | 100 µg | EUR 818.4 |
Description: EBNA1 (EBV) (P03211) partial recombinant protein with GST tag expressed in E. coli. |
EBNA1 Binding Protein 2 Protein |
|||
20-abx260778 | Abbexa |
|
|
EBNA1 Binding Protein 2 (EBNA1BP2) Antibody |
|||
abx026949-400ul | Abbexa | 400 ul | EUR 627.6 |
EBNA1 Binding Protein 2 (EBNA1BP2) Antibody |
|||
abx026949-80l | Abbexa | 80 µl | EUR 343.2 |
EBNA1 Binding Protein 2 (EBNA1BP2) Antibody |
|||
20-abx123650 | Abbexa |
|
|
EBNA1BP2 EBNA1 Binding Protein 2 Human Recombinant Protein |
|||
PROTQ99848 | BosterBio | Regular: 20ug | EUR 380.4 |
Description: Recombinant Human EBNA1BP2 produced in E. coli is a single polypeptide chain containing 329 amino acids (1-306) and having a molecular mass of 37.2kDa.;EBNA1BP2 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
Recombinant (E.Coli, GST tag) Epstein-Barr Virus (EBV/HHV-4) Mosaic EBNA1 |
|||
RP-347 | Alpha Diagnostics | 100 ug | EUR 343.2 |
Recombinant EBNA1 Protein [His] (1.185 mg/mL) |
|||
VAng-0610Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: Epstein-Barr Virus (EBV) Nuclear Antigen-1 (EBNA-1), recombinant protein from E. coli. MW 63 kDa, 1.185 mg/mL. |
Recombinant EBNA1 Protein [His] (1.25 mg/mL) |
|||
VAng-0611Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: Epstein-Barr Virus (EBV) Nuclear Antigen-1 (EBNA-1), recombinant protein from E. coli. MW 63 kDa, 1.25 mg/mL. |
Epstein-Barr Virus (HHV-4) EBNA1 Protein |
|||
20-abx260340 | Abbexa |
|
|
Mouse EBNA1 Binding Protein 2 (EBNA1BP2) ELISA Kit |
|||
abx389130-96tests | Abbexa | 96 tests | EUR 1093.2 |
Human EBNA1 Binding Protein 2 (EBNA1BP2) ELISA Kit |
|||
abx384822-96tests | Abbexa | 96 tests | EUR 1093.2 |
Ebna1bp2 (GFP-tagged) - Mouse EBNA1 binding protein 2 (Ebna1bp2) |
|||
MG204306 | Origene Technologies GmbH | 10 µg | Ask for price |
Ebna1bp2 (untagged) - Mouse EBNA1 binding protein 2 (Ebna1bp2), (10ug) |
|||
MC202488 | Origene Technologies GmbH | 10 µg | Ask for price |
Recombinant EBNA1 Protein (aa 1-90, 408-498) [GST] |
|||
VAng-Lsx0128-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBV NA1 (aa 1-90, 408-498) [GST], recombinant protein from E. coli. |
Epstein-Barr Virus (HHV-4) Mosaic EBNA1 Protein |
|||
20-abx260113 | Abbexa |
|
|
EBV EBNA-3A 38 kDa |
|||
PR-1446-L | Jena Bioscience GmbH | 1mg | EUR 1307.3 |
Description: recombinant, E. coli |
EBV EBNA-3A 38 kDa |
|||
PR-1446-S | Jena Bioscience GmbH | 200µg | EUR 326.7 |
Description: recombinant, E. coli |
Ebna1bp2 (Myc-DDK-tagged) - Mouse EBNA1 binding protein 2 (Ebna1bp2) |
|||
MR204306 | Origene Technologies GmbH | 10 µg | Ask for price |
Ebna1bp2 (untagged ORF) - Rat EBNA1 binding protein 2 (Ebna1bp2), (10 ug) |
|||
RN214064 | Origene Technologies GmbH | 10 µg | Ask for price |
Epstein-Barr Virus (EBV) Epstein-Bar Nuclear Antigen-1 (EBNA-1) Protein |
|||
abx061529-1mg | Abbexa | 1 mg | EUR 2030.4 |
EBNA1BP2 (untagged)-Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 2 |
|||
SC320280 | Origene Technologies GmbH | 10 µg | Ask for price |
EBNA1BP2 (untagged)-Human EBNA1 binding protein 2 (EBNA1BP2) transcript variant 1 |
|||
SC326927 | Origene Technologies GmbH | 10 µg | Ask for price |
EBV EBNA-1 IgG ELISA Kit |
|||
DEIA332 | Creative Diagnostics | 96T | EUR 618 |
Description: The EBVEBNA-1 IgG Antibody ELISA Test Kit has been designed for the the detectionand the quantitative determination of specific IgG antibodies against EBVEBNA-1 in serum and plasma. |
EBV EBNA-1 IgA ELISA Kit |
|||
DEIA333 | Creative Diagnostics | 96T | EUR 618 |
Description: The EBVEBNA-1 IgA Antibody ELISA Test Kit has been designed for the the detectionand the quantitative determination of specific IgA antibodies against EBVEBNA-1 in serum and plasma. |
EBV EBNA-1 IgM ELISA Kit |
|||
DEIA334 | Creative Diagnostics | 96T | EUR 618 |
Description: The EBVEBNA-1 IgM Antibody ELISA Test Kit has been designed for the the detectionand the quantitative determination of specific IgM antibodies against EBVEBNA-1 in serum and plasma. |
EBV EBNA-1 mosaic 45 kDa |
|||
PR-1447-L | Jena Bioscience GmbH | 1mg | EUR 1958.7 |
Description: recombinant, E. coli |
EBV EBNA-1 mosaic 45 kDa |
|||
PR-1447-S | Jena Bioscience GmbH | 200µg | EUR 489.8 |
Description: recombinant, E. coli |
pCXWB- EBNA1 |
|||
PVT10196 | Lifescience Market | 2 ug | EUR 361.2 |
Ebna1bp2 (Myc-DDK-tagged ORF) - Rat EBNA1 binding protein 2 (Ebna1bp2), (10 ug) |
|||
RR214064 | Origene Technologies GmbH | 10 µg | Ask for price |
EBNA1BP2 (GFP-tagged) - Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 1 |
|||
RG228292 | Origene Technologies GmbH | 10 µg | Ask for price |
EBNA1BP2 (GFP-tagged) - Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 2 |
|||
RG200250 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Ebna1bp2 (mGFP-tagged) - Mouse EBNA1 binding protein 2 (Ebna1bp2) |
|||
MR204306L4 | Origene Technologies GmbH | 10 µg | Ask for price |
EBNA1BP2 (Myc-DDK-tagged)-Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 2 |
|||
RC200250 | Origene Technologies GmbH | 10 µg | Ask for price |
EBNA1BP2 (Myc-DDK-tagged)-Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 1 |
|||
RC228292 | Origene Technologies GmbH | 10 µg | Ask for price |
EBV antigen EBNA-1 Antibody |
|||
abx140258-01mg | Abbexa | 0.1 mg | EUR 393.6 |
Lenti ORF clone of Ebna1bp2 (Myc-DDK-tagged) - Mouse EBNA1 binding protein 2 (Ebna1bp2) |
|||
MR204306L3 | Origene Technologies GmbH | 10 µg | Ask for price |
EBNA1-IN-SC7 |
|||
T62921-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: EBNA1-IN-SC7 |
EBNA1-IN-SC7 |
|||
T62921-1g | TargetMol Chemicals | 1g | Ask for price |
Description: EBNA1-IN-SC7 |
EBNA1-IN-SC7 |
|||
T62921-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: EBNA1-IN-SC7 |
EBNA1-IN-SC7 |
|||
T62921-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: EBNA1-IN-SC7 |
EBNA1-IN-SC7 |
|||
T62921-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: EBNA1-IN-SC7 |
EBNA1 binding protein 2 (EBNA1BP2) (C-term) rabbit polyclonal antibody, Aff - Purified |
|||
AP51355PU-N | Origene Technologies GmbH | 400 µl | Ask for price |
pCXWB- EBNA1 Plasmid |
|||
PVT7175 | Lifescience Market | 2 ug | EUR 319.2 |
Lenti ORF clone of Ebna1bp2 (mGFP-tagged ORF) - Rat EBNA1 binding protein 2 (Ebna1bp2), (10 ug) |
|||
RR214064L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Ebna1bp2 (Myc-DDK-tagged ORF) - Rat EBNA1 binding protein 2 (Ebna1bp2), (10 ug) |
|||
RR214064L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, Ebna1bp2 (GFP-tagged) - Mouse EBNA1 binding protein 2 (Ebna1bp2), 200ul, >10^7 TU/mL |
|||
MR204306L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Ebna1bp2 (GFP-tagged ORF) - Rat EBNA1 binding protein 2 (Ebna1bp2), 200ul, >10^7 TU/mL |
|||
RR214064L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF clone of Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 2, mGFP tagged |
|||
RC200250L2 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 2, mGFP tagged |
|||
RC200250L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 1, mGFP tagged |
|||
RC228292L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, Ebna1bp2 (Myc-DDK-tagged) - Mouse EBNA1 binding protein 2 (Ebna1bp2), 200ul, >10^7 TU/mL |
|||
MR204306L3V | Origene Technologies GmbH | 200 µl | Ask for price |
EBNA1 (RFP-Bsd) Lentivirus |
|||
LVP1134-RB | GenTarget | 1x107 IFU/ml x 200ul | EUR 418.8 |
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA1 gene under EF1a promoter, containing RFP-Blasticidin dual marker. |
EBNA1 (GFP-Puro) Lentivirus |
|||
LVP1134-GP | GenTarget | 1x107 IFU/ml x 200ul | EUR 418.8 |
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA1 gene under EF1a promoter, containing GFP-Puromycin dual marker. |
Lenti ORF particles, Ebna1bp2 (Myc-DDK-tagged ORF) - Rat EBNA1 binding protein 2 (Ebna1bp2), 200ul, >10^7 TU/mL |
|||
RR214064L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF clone of Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 2, Myc-DDK-tagged |
|||
RC200250L1 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 2, Myc-DDK-tagged |
|||
RC200250L3 | Origene Technologies GmbH | 10 µg | Ask for price |
3`UTR clone of EBNA1 binding protein 2 (EBNA1BP2) transcript variant 1 for miRNA target validation |
|||
SC203577 | Origene Technologies GmbH | 10 µg | Ask for price |
3`UTR clone of EBNA1 binding protein 2 (EBNA1BP2) transcript variant 2 for miRNA target validation |
|||
SC203579 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 1, Myc-DDK-tagged |
|||
RC228292L3 | Origene Technologies GmbH | 10 µg | Ask for price |
OAEE00388-100UG - EBNA1 Antibody |
|||
OAEE00388-100UG | Aviva Systems Biology | 0.1mg | EUR 169 |
Lenti ORF particles, EBNA1BP2 (mGFP-tagged) - Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 2, 200ul, >10^7 TU/mL |
|||
RC200250L2V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, EBNA1BP2 (mGFP-tagged) - Human EBNA1 binding protein 2 (EBNA1BP2), transcript variant 2, 200ul, >10^7 TU/mL |
|||
RC200250L4V | Origene Technologies GmbH | 200 µl | Ask for price |